GSK973 is a highly selective, orally bioavailable inhibitor of the BET family BD2 domains; it exhibits potent inhibitory activity against BRD4-BD2 (pIC50 = 7.8, pKd = 8.7) with 1600-fold selectivity over BRD4-BD1, and also shows strong inhibition against BRD2-BD2, BRD3-BD2, and BRDT-BD2 (pIC50 = 7.4–7.8; pKd = 8.3–8.5).